p53 mutations occur very frequently in human cancer. Besides abrogating the tumour suppressive functions of wild-type p53, many of those mutations also acquire oncogenic gain-of-function activities. Augmentation of proteasome activity is now reported as a common gain-of-function mechanism shared by different p53 mutants, which promotes cancer resistance to proteasome inhibitors.
This is a preview of subscription content, log in via an institution to check access.
References
Olivier, M. & Taniere, P. Curr. Opin. Oncol. 23, 88–92 (2011).
Rotter, V. Proc. Natl Acad. Sci. USA 80, 2613–2617 (1983).
Oren, M. & Rotter, V. Cold Spring Harb. Perspect. Biol. 2, a001107 (2010).
Freed-Pastor, W. A. & Prives, C. Genes Dev. 26, 1268–1286 (2012).
Kato, S. et al. Proc. Natl Acad. Sci. USA 100, 8424–8429 (2003).
Zhu, J. et al. Nature 525, 206–211 (2015).
Walerych, D. et al. Nat. Cell Biol. 18, 897–909 (2016).
DeNicola, G. M. et al. Nature 475, 106–109 (2011).
Tung, M. C. et al. Oncotarget 6, 41692–41705 (2015).
Hershko, A. & Ciechanover, A. Annu. Rev. Biochem. 67, 425–479 (1998).
Vogelstein, B. et al. Science 339, 1546–1558 (2013).
Deshaies, R. J. BMC Biol. 12, 94 (2014).
Richardson, P. G. et al. N. Engl. J. Med. 352, 2487–2498 (2005).
O'Connor, O. A. et al. J. Clin. Oncol. 23, 676–684 (2005).
Brosh, R. & Rotter, V. Nat. Rev. Cancer 9, 701–713 (2009).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Oren, M., Kotler, E. p53 mutations promote proteasomal activity. Nat Cell Biol 18, 833–835 (2016). https://doi.org/10.1038/ncb3392
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb3392
- Springer Nature Limited